Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

You may be eligible if

• Histologically or cytologically confirmed non-small cell lung cancer
• * Selected stage IIIB (malignant pleural effusion) or stage IV disease
• * Recurrent disease after first-line therapy allowed
• Patients who received prior platinum-based chemotherapy must have no disease progression during or within 3 months after completion of therapy
• * Patients who are enrolled at the maximum tolerated dose must have chemotherapy-naïve disease
• Evaluable disease
• Asymptomatic brain metastases allowed if treated with surgical resection or radiotherapy, neurologically stable, and off steroids for at least 4 weeks
• Performance status - Karnofsky 60-100%
• More than 3 months
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Bilirubin no greater than 1.5 mg/dL
• AST no greater than 2.5 times upper limit of normal
• Creatinine normal
• Creatinine clearance at least 50 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No peripheral neuropathy grade 2 or greater
• No prior allergic reactions to compounds of similar chemical or biological composition to bortezomib or other agents used in this study
• No concurrent ongoing or active infection
• No other concurrent uncontrolled illness
• No psychiatric illness or social situation that would preclude study compliance
• No concurrent routine filgrastim (G-CSF)
• See Disease Characteristics
• No more than 1 prior chemotherapy regimen
• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
• No prior gemcitabine
• See Disease Characteristics
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and recovered
• See Disease Characteristics
• More than 30 days since prior investigational drugs
• No prior bortezomib
• No concurrent anticonvulsant therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational or commercial agents or therapies with intent to treat malignancy